MedTrace Logo

Empagliflozin vs Metformin on Metabolic Dysfunction in Polycystic Ovary Syndrome With or Without Comorbidity or Multimorbidity

NCT06140108 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2025-05-14

No results posted yet for this study

Summary

this is open labelled randomize control trial among women with PCOS. PCOS, an endocrine condition, affects 5%-15% of premenopausal women. PCOS is characterized by atypical menstruation, ovulation difficulties, hyperandrogenemia, insulin resistance, and other metabolic abnormalities. Metformin is now an option for PCOS. The clinical reactions to metformin are limited and varied. Novel SGLT2 inhibitors treat type 2 diabetes with weight loss, insulin resistance reduction, and cardiovascular benefits. There is little evidence on SGLT2 inhibitor effectiveness in PCOS patients.

Conditions

  • Polycystic Ovary Syndrome
  • Weight Gain
  • HbA1c

Interventions

DRUG

Empagliflozin 10 MG

Each participant will receive empagliflozin 10mg daily for 6 months.

DRUG

MetFORMIN 500 Mg Oral Tablet

Each participant will receive metformin 1000mg daily for 6 months.

Sponsors & Collaborators

  • SINA Health Education and Welfare Trust

    lead OTHER

Principal Investigators

  • Hina Sharif, PharmD,MSPH · SINA Health Education & Welfare Trust

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
49 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-15
Primary Completion
2024-05-30
Completion
2024-06-30

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06140108 on ClinicalTrials.gov